Nonarteritic Anterior Ischemic Optic Neuropathy

The cover story in this issue of Healio | OSN provides a comprehensive review of obstructive sleep apnea and its potential impact on the body and eye. I will emphasize a few of the extensive points discussed.

Obstructive sleep apnea is a common breathing-related sleep disorder, with a growing prevalence due to the aging population and the rise of obesity.

Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using semaglutide therapy than when they are not using the drug, according to findings from a retrospective study.

Recent research has suggested that GLP-1 agonists used to treat obesity might be associated with a stroke in the optic nerve, but association is not the same as causation.

A paper recently published in JAMA Ophthalmology by Hathaway and colleagues at Harvard suggested a potential association between prescribed semaglutide and an increased risk for nonarteritic anterior ischemic optic neuropathy.

Drugs utilized to treat systemic diseases can do harm to the eye and its neural connections.

A deep learning system achieved an accuracy of more than 90% in distinguishing arteritic from nonarteritic anterior ischemic optic neuropathy using only color fundus images, according to a study published in JAMA Ophthalmology.

Adults using a GLP-1 receptor agonist do not have increased risk for nonarteritic anterior ischemic optic neuropathy, according to data from a retrospective analysis published in Journal of Diabetes Science and Technology.

Semaglutide was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy — a form of optic neuropathy that can cause blindness — in adults with type 2 diabetes or obesity, recent data show.

Age-related macular degeneration is the leading cause of vison loss among older adults.